The Netherlands will expand its export restrictions on some of ASML’s chip- manufacturing equipment, the Dutch government said Friday. The restrictions come as the U.S. and its allies seek to curb China’s access to critical technologies, such as advanced chips, that could be used for military applications.
Colombian startup Rappi, which is backed by Japan's SoftBank, could be ready to launch an initial public offering on the New York Stock Exchange within 12 months, cofounder Simon Borrero said on Monday. "It's within our plan to go public, it could be on the New York Stock Exchange," Borrero told reporters. "The idea is that as a company, in 12 months, we will be ready to come out with all the audit processes, with mature projections as well."
This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMN
Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in mental health and addiction care Vancouver, Canada, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent applic
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET. To register for the live webcast, please click here. The webcast will also be available on the Company’s websi
SAN CARLOS, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Oportun (Nasdaq: OPRT), a mission-driven fintech, today announced that it will participate in the upcoming Sidoti September Virtual Investor Conference. Oportun’s Chief Executive Officer, Raul Vazquez, and Chief Financial Officer & Chief Administrative Officer, Jonathan Coblentz, will present and participate in investor meetings at the conference. The presentation will begin at 2:30 pm ET on September 18th and can be accessed live at this li
MILWAUKEE, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Enerpac Tool Group Corp. (NYSE: EPAC) announced today that it will release its fourth quarter fiscal 2024 earnings after the market closes on Tuesday, October 15, 2024. Management will conduct a conference call to discuss the results on Wednesday, October 16, 2024, beginning at 8:30 a.m. ET / 7:30 a.m. CT. A real-time webcast of the conference call can be accessed via the Investors section of the Company’s website here. For those who are unavailable
MONTREAL, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, declared a quarterly dividend of US $0.40 per outstanding common share of its capital payable on October 15, 2024 to shareholders of record at the close of business on September 30, 2024. ABOUT TFI INTERNATIONAL TFI International Inc. is a North American leader in the transportation and logistics industry, operat
REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:00 AM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.sole
The parent company of Five Star Bank plans to initiate an orderly wind down process for its Banking-as-a-Service offerings, which as of June 30, 2024 represented about 2% of deposits and under 1% of loansWARSAW, N.Y., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Financial Institutions, Inc. (NASDAQ: FISI) (the "Company," "we" or "us"), a diversified financial services company and parent company of Five Star Bank (the “Bank”) and Courier Capital, LLC (“Courier Capital”), today announced its intent to begin
CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the closing of its previously announced upsized initial public offering of 11,730,000 of its common stock at a price to the public of $16.00 per share, which includes 1,530,000 shares issued upon the e
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.
'TMZ Investigates: Matthew Perry and the Secret Celebrity Drug Ring' premieres Monday, Sept. 16, at 9/8c on FOX and streams on Hulu
All eyes are on the Federal Reserve this week as the central bank is set to kick off its interest rate easing cycle on Wednesday, September 18. Piper Sandler chief investment strategist Michael Kantrowitz joins Market Domination to discuss the Fed's rate cut path ahead of its September FOMC meeting. While Wall Street is divided between a 25 and 50-basis-point cut, Kantrowitz believes 25 is more likely despite wanting to see a 50-point cut. "I think he [Fed Chair Powell] wants to avoid maybe doing 50 unless it's really necessary to set the expectation they're going to be cutting rates that quickly. But on the flip side, I think they should do 50, and I guess we'll see how confident Powell really is," he explains. Overall, Kantrowitz believes that the size of the cut won't make a "big difference" for markets. Instead, the focus will likely be on the rate-cut path ahead. He notes that September is expected to see unemployment tick higher as the labor market slows. Overall, Kantrowitz believes it is "possible" that the market will see the 100 basis points worth of cuts it has currently priced in. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
The fourteen tracks span from 'Speak Now' to 'The Tortured Poets Department'
"Anything I can do to mitigate any sort of brain injury or long term health effects that would be detrimental to me takes precedent," Granson said
The character’s nearest and dearest are going to be left desperately trying to work out how to raise the funds needed to allow her to be discharged after she failed to disclose the surgery to her insurance
In recent weeks, Japan's stock markets have shown mixed performance with the Nikkei 225 Index gaining 0.5% while the broader TOPIX Index declined by 1.0%. Amid currency headwinds and a cautious economic outlook, investors are increasingly focusing on growth companies with strong insider ownership as potential opportunities. A good stock in this context is often characterized by robust growth prospects and significant insider ownership, which can indicate confidence in the company's future...
Ascendis Pharma stock rocketed Monday on promising test results for a growth treatment that could rival BioMarin's approved drug, Voxzogo.
Yahoo Finance